Clinical features at transformation in adult T-cell leukemia–lymphoma with smoldering and chronic types

被引:0
作者
Hiroaki Taniguchi
Yoshitaka Imaizumi
Yumi Takasaki
Jun Nakashima
Takeharu Kato
Hidehiro Itonaga
Shinya Sato
Yasushi Sawayama
Koji Ando
Hiroo Hasegawa
Tomoko Hata
Yukiyoshi Moriuchi
Kunihiro Tsukasaki
Yasushi Miyazaki
机构
[1] Sasebo City General Hospital,Department of Hematology
[2] Nagasaki University Hospital,Department of Hematology
[3] Saint Francis Hospital,Department of Hematology
[4] Nagasaki University Hospital,Department of Laboratory Medicine
[5] Saitama Medical University,Department of Hematology, International Medical Center
来源
International Journal of Hematology | 2019年 / 109卷
关键词
Adult T-cell leukemia–lymphoma (ATL); Transformation; Smoldering; Chronic;
D O I
暂无
中图分类号
学科分类号
摘要
Watchful waiting (WW) is among the treatment options indicated for patients with indolent adult T-cell leukemia–lymphoma (ATL). However, we previously showed that the long-term prognosis of patients with smoldering and chronic ATL is often worse than expected, with many undergoing transformation to aggressive ATL. To identify clinical features associated with transformation of smoldering/chronic ATL, we retrospectively analyzed the clinical features of 44 patients (14 smoldering and 30 chronic) who experienced transformation during WW. An elevated lactate dehydrogenase (LDH) value was most often observed (n = 30) at the time of transformation, especially in the chronic type (n = 24). Major organ involvement, lymphadenopathy, and hypercalcemia were shown to be associated with transformation in transformed patients without elevated LDH. The median overall survival time after transformation was only 7.8 months, and the prognosis was poor after transformation in those fulfilling the criteria of acute type, similar to that of de novo aggressive ATL. Laboratory data, such as LDH, and clinical signs including exacerbation of performance status, skin lesions, and lymphadenopathy should all be monitored during WW to ensure appropriate timing of chemotherapy initiation. Identification of optimal predictive markers for transformation and new therapeutic options is warranted to improve outcomes in indolent ATL.
引用
收藏
页码:402 / 408
页数:6
相关论文
共 88 条
[1]  
Tsukasaki K(2014)Human T-cell lymphotropic virus type I-associated adult T-cell leukemia-lymphoma: new directions in clinical research Clin Cancer Res 20 5217-5225
[2]  
Tobinai K(1991)Diagnostic criteria and classification of clinical subtypes of adult T-cell leukaemia-lymphoma. A report from the Lymphoma Study Group (1984–87) Br J Haematol 79 428-437
[3]  
Shimoyama M(2015)Treatment and survival among 1594 patients with ATL Blood 126 2570-2577
[4]  
Katsuya H(2010)Long-term study of indolent adult T-cell leukemia-lymphoma Blood 115 4337-4343
[5]  
Ishitsuka K(2009)Definition, prognostic factors, treatment, reesponse criteria of adult T-cell leukemia-lymphoma: a proposal from an international consensus meeting J Clin Oncol 27 453-459
[6]  
Utsunomiya A(1997)Deletion of p15 and/or p16 genes as a poor-prognosis factor in adult T-cell leukemia J Clin Oncol 15 1778-1785
[7]  
Hanada S(2003)Interruption of p16 gene expression in adult T-cell leukaemia/lymphoma: clinical correlation Br J Haematol 122 253-259
[8]  
Eto T(2001)Comparative genomic hybridization analysis in adult T-cell leukemia/lymphoma: correlation with clinical course Blood 97 3875-3881
[9]  
Moriuchi Y(2017)Prognostic index for chronic- and smoldering-type adult T-cell leukemia-lymphoma Blood 130 39-47
[10]  
Takasaki Y(2018)Prognostic relevance of integrated genetic profiling in adult T-cell leukemia/lymphoma Blood 131 215-225